The combination treatment of GBM cells with IL-2 and recombinant human p53 adenovirus injection (rAd-p53) not only stimulated specific immune responses against GBM cells, but also increased the proliferation of regulatory CD4+ and cytotoxic CD8+ T cells [47]. The gene discussed is CD8A; the disease is glioblastoma.